HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benzinga · 2d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.